Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response
Korneliusz Golebski,Janice A Layhadi,Umit Sahiner,Esther H Steveling-Klein,Madison M Lenormand,Rachael C Y Li,Suzanne M Bal,Balthasar A Heesters,Gemma Vilà-Nadal,Oliver Hunewald,Guillem Montamat,Feng Q He,Markus Ollert,Oleksandra Fedina,Mongkol Lao-Araya,Susanne J H Vijverberg,Anke-Hilse Maitland-van der Zee,Cornelis M van Drunen,Wytske J Fokkens,Stephen R Durham,Hergen Spits,Mohamed H Shamji,Janice A. Layhadi,Esther H. Steveling-Klein,Madison M. Lenormand,Rachael C.Y. Li,Suzanne M. Bal,Balthasar A. Heesters,Feng Q. He,Susanne J.H. Vijverberg,Cornelis M. van Drunen,Wytske J. Fokkens,Stephen R. Durham,Mohamed H. Shamji
DOI: https://doi.org/10.1016/j.immuni.2020.12.013
IF: 32.4
2021-02-01
Immunity
Abstract:The role of innate immune cells in allergen immunotherapy that confers immune tolerance to the sensitizing allergen is unclear. Here, we report a role of interleukin-10-producing type 2 innate lymphoid cells (IL-10 <sup>+</sup> ILC2s) in modulating grass-pollen allergy. We demonstrate that KLRG1 <sup>+</sup> but not KLRG1 <sup>–</sup> ILC2 produced IL-10 upon activation with IL-33 and retinoic acid. These cells attenuated Th responses and maintained epithelial cell integrity. IL-10 <sup>+</sup> KLRG1 <sup>+</sup> ILC2s were lower in patients with grass-pollen allergy when compared to healthy subjects. In a prospective, double-blind, placebo-controlled trial, we demonstrated that the competence of ILC2 to produce IL-10 was restored in patients who received grass-pollen sublingual immunotherapy. The underpinning mechanisms were associated with the modification of retinol metabolic pathway, cytokine-cytokine receptor interaction, and JAK-STAT signaling pathways in the ILCs. Altogether, our findings underscore the contribution of IL-10 <sup>+</sup> ILC2s in the disease-modifying effect by allergen immunotherapy.
immunology